tiprankstipranks
Trending News
More News >
Helius Medical Technologies (HSDT)
NASDAQ:HSDT
US Market

Helius Medical Technologies (HSDT) Price & Analysis

Compare
391 Followers

HSDT Stock Chart & Stats

$2.82
-$0.04(-5.47%)
At close: 4:00 PM EST
$2.82
-$0.04(-5.47%)

Bulls Say, Bears Say

Bulls Say
Clinical ResultsHSDT announced positive results from the PoNS Therapeutic Experience Program, or PoNSTEP, study for people with multiple sclerosis.
Partnerships And ApprovalsUnitedHealthcare has approved reimbursement for the PoNS device, adding a second private payer to provide coverage.
Bears Say
Financial PerformanceHSDT reported lower-than-expected 1Q25 revenue, as adoption of the PoNS device remains inconsistent.
Reimbursement ChallengesThe ongoing reimbursement headwind continues to limit access to key patient populations and suppress near-term growth.

Helius Medical Technologies News

HSDT FAQ

What was Helius Medical Technologies’s price range in the past 12 months?
Helius Medical Technologies lowest stock price was $2.83 and its highest was $1200.00 in the past 12 months.
    What is Helius Medical Technologies’s market cap?
    Helius Medical Technologies’s market cap is $123.08M.
      When is Helius Medical Technologies’s upcoming earnings report date?
      Helius Medical Technologies’s upcoming earnings report date is May 07, 2026 which is in 134 days.
        How were Helius Medical Technologies’s earnings last quarter?
        Helius Medical Technologies released its earnings results on Nov 18, 2025. The company reported -$32.89 earnings per share for the quarter, beating the consensus estimate of -$50.5 by $17.61.
          Is Helius Medical Technologies overvalued?
          According to Wall Street analysts Helius Medical Technologies’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Helius Medical Technologies pay dividends?
            Helius Medical Technologies does not currently pay dividends.
            What is Helius Medical Technologies’s EPS estimate?
            Helius Medical Technologies’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Helius Medical Technologies have?
            Helius Medical Technologies has 41,301,400 shares outstanding.
              What happened to Helius Medical Technologies’s price movement after its last earnings report?
              Helius Medical Technologies reported an EPS of -$32.89 in its last earnings report, beating expectations of -$50.5. Following the earnings report the stock price went down -6%.
                Which hedge fund is a major shareholder of Helius Medical Technologies?
                Currently, no hedge funds are holding shares in HSDT
                What is the TipRanks Smart Score and how is it calculated?
                Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                  Company Description

                  Helius Medical Technologies

                  Solana Co. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.

                  Helius Medical Technologies (HSDT) Earnings & Revenues

                  HSDT Earnings Call

                  Q3 2025
                  0:00 / 0:00
                  Earnings Call Sentiment|Neutral
                  The earnings call highlighted significant achievements in fundraising and strategic advocacy, leading to increased Solana holdings and positive clinical outcomes for the PoNS device. However, these positives were offset by substantial financial losses and increased operating expenses, with the digital asset treasury market showing signs of cooling.View all HSDT earnings summaries
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Sanuwave Health
                  Viemed Healthcare
                  Outset Medical
                  CVRx
                  Sight Sciences

                  Ownership Overview

                  0.94%<0.01%21.64%77.40%
                  0.94%
                  Insiders
                  21.64% Other Institutional Investors
                  77.40% Public Companies and
                  Individual Investors
                  Popular Stocks